776 related articles for article (PubMed ID: 21367600)
21. Effects of communicating social comparison information on risk perceptions for colorectal cancer.
Lipkus IM; Klein WM
J Health Commun; 2006 Jun; 11(4):391-407. PubMed ID: 16720537
[TBL] [Abstract][Full Text] [Related]
22. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
23. Fecal occult blood testing instructions and impact on patient adherence.
Bapuji SB; Lobchuk MM; McClement SE; Sisler JJ; Katz A; Martens P
Cancer Epidemiol; 2012 Aug; 36(4):e258-64. PubMed ID: 22504053
[TBL] [Abstract][Full Text] [Related]
24. Colorectal cancer screening.
Bretthauer M
J Intern Med; 2011 Aug; 270(2):87-98. PubMed ID: 21575082
[TBL] [Abstract][Full Text] [Related]
25. [Screening of high-risk group with colorectal cancer].
Xu AG; Yu ZJ; Zhong XH; Gan AH; Liu JH; Luo QY
Zhonghua Yi Xue Za Zhi; 2010 Jan; 90(2):116-8. PubMed ID: 20356496
[TBL] [Abstract][Full Text] [Related]
26. Attitudes, knowledge and practice of CRC screening among GPs in Queensland.
Youl PH; Jackson C; Oldenburg B; Brown C; Dunn J; Aitken J
Aust Fam Physician; 2006 Jul; 35(7):547-50. PubMed ID: 16820832
[TBL] [Abstract][Full Text] [Related]
27. A population-based estimate of the extent of colorectal cancer screening in Ontario.
Rabeneck L; Paszat LF
Am J Gastroenterol; 2004 Jun; 99(6):1141-4. PubMed ID: 15180738
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
[TBL] [Abstract][Full Text] [Related]
29. Comparison of guaiac and immunological fecal occult blood tests in colorectal cancer screening: the patient perspective.
Deutekom M; van Rossum LG; van Rijn AF; Laheij RJ; Fockens P; Bossuyt PM; Dekker E; Jansen JB
Scand J Gastroenterol; 2010 Nov; 45(11):1345-9. PubMed ID: 20560814
[TBL] [Abstract][Full Text] [Related]
30. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
31. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
[TBL] [Abstract][Full Text] [Related]
32. Screening colonoscopy and fecal occult blood testing practice patterns: a population-based survey of gastroenterologists.
Rossi F; Sosa JA; Aslanian HR
J Clin Gastroenterol; 2008; 42(10):1089-94. PubMed ID: 18936643
[TBL] [Abstract][Full Text] [Related]
33. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
Clarke P; Jack F; Carey FA; Steele RJ
Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
[TBL] [Abstract][Full Text] [Related]
34. Adherence to follow-up after a positive fecal occult blood test in an organized colorectal cancer screening program in Korea, 2004-2008.
Choi KS; Lee HY; Jun JK; Shin A; Park EC
J Gastroenterol Hepatol; 2012 Jun; 27(6):1070-7. PubMed ID: 22004224
[TBL] [Abstract][Full Text] [Related]
35. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness of the FLU-FOBT program in primary care a randomized trial.
Potter MB; Walsh JM; Yu TM; Gildengorin G; Green LW; McPhee SJ
Am J Prev Med; 2011 Jul; 41(1):9-16. PubMed ID: 21665058
[TBL] [Abstract][Full Text] [Related]
37. [Screening for colorectal cancer in high-risk and intermediate-risk subject: what's the best tool?].
Trevisani L; Cifalà V; Sartori S; Tombesi P; Matarese V; Pezzoli A; Abbasciano V
Recenti Prog Med; 2009 Feb; 100(2):68-72. PubMed ID: 19350797
[TBL] [Abstract][Full Text] [Related]
38. Fecal occult blood testing: a false sense of security?
Schnell T; Aranha GV; Sontag SJ; Tode R; Reid S; Chejfec G; Karpf J; Levine G
Surgery; 1994 Oct; 116(4):798-802; discussion 802-3. PubMed ID: 7940181
[TBL] [Abstract][Full Text] [Related]
39. Colonoscopy results of a French regional FOBT-based colorectal cancer screening program with high compliance.
Manfredi S; Piette C; Durand G; Plihon G; Mallard G; Bretagne JF
Endoscopy; 2008 May; 40(5):422-7. PubMed ID: 18231963
[TBL] [Abstract][Full Text] [Related]
40. Risk stratification and detection of new colorectal neoplasms after colorectal cancer screening with faecal occult blood test: experiences from a Danish screening cohort.
Bjerrum A; Milter MC; Andersen O; Fischer A; Lynge E
Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1433-7. PubMed ID: 26352132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
